Competitive AdvantageJADE-001 is expected to emerge as the optimal disease-modifying therapy and could capture a significant share of a multibillion-dollar market.
LeadershipJade Biosciences is led by a world-class team that previously sold an IgAN portfolio to Novartis for a significant amount, indicating strong leadership and expertise.
Product PerformanceJADE-001 is a potential best-in-class, pure anti-APRIL mAb with 755x greater potency than Otsuka's sibe.